Mixtard 30 (Insulin Human)

Insulin human, the active ingredient in Mixtard 30, is an insulin presented as a 100 U/mL premixed injectable solution for subcutaneous use. It is employed to manage blood glucose levels in individuals with type 1 or type 2 diabetes mellitus, providing both basal and prandial insulin action.

GNH USA supplies Mixtard 30 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for this biologic product. These deliveries are made through regulated distribution networks.

Mixtard 30 is an insulin preparation used in the management of diabetes mellitus.

Type 1 diabetes mellitus: supplies both basal and rapid‑acting insulin components, helping patients achieve stable blood glucose levels and reduce the risk of hypoglycaemic episodes. Type 2 diabetes mellitus: adds a premixed insulin regimen when diet, exercise, and oral hypoglycaemic agents are insufficient, facilitating improved glycaemic control and simplifying injection schedules.

Mixtard 30 may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dose is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with insulin therapy. - Lipodystrophy: localized fat accumulation or loss at injection sites.

Serious or Rare Side Effects: - Severe hypoglycaemia: seizures or loss of consciousness requiring assistance. - Anaphylactic reaction: rare systemic allergic response that may be life‑threatening. - Insulin edema: fluid retention leading to peripheral swelling. - Hypokalemia: low serum potassium levels in rare cases.

When using Mixtard 30, several precautions should be observed to ensure safe and effective therapy. - Blood glucose monitoring: check levels regularly to adjust dose and avoid hypoglycaemia. - Dose adjustment during illness: reduce or increase insulin based on carbohydrate intake and stress. - Caution in renal impairment: impaired clearance may increase risk of prolonged insulin action. - Use during pregnancy: safety category is unknown; prescribe only if benefits outweigh potential risks. - Avoid use in hypoglycaemia: do not administer if patient is already experiencing low blood glucose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Mixtard 30 can interact with other medicines, altering its glucose‑lowering effect or masking symptoms.

Major Interactions (Avoid): - Sulfonylureas: combined use may cause severe hypoglycaemia. - Beta‑blockers: may mask typical hypoglycaemia warning signs such as tachycardia. - Alcohol: excessive intake can potentiate insulin’s glucose‑lowering action leading to hypoglycaemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, increasing hypoglycaemia risk. - Corticosteroids: can raise blood glucose, potentially requiring higher insulin doses. - Thiazide diuretics: may impair glucose tolerance, necessitating dose adjustments. - Oral contraceptives: hormonal changes can affect insulin requirements.